Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled …

HAYWARD, Calif.–(BUSINESS WIRE)–Aradigm selects Pulmaquin™ for Phase 3 development and announces issuance of its first U.S. patent covering inhaled ciprofloxacin formulations.

Leave a Reply

Your email address will not be published.

*